GLAXO2019-10-012019-12-31in-bse-fin:OneOperatingExpenses01Member GLAXO2019-10-012019-12-31in-bse-fin:FourOperatingExpenses01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares GLAXO 2019-04-01 2020-03-31 2019-12-27 INR Lakhs Third quarter Single segment Pharmaceuticals 2019-10-01 2019-12-31 Unaudited Standalone 7786800000.00 162500000.00 7949300000.00 1124500000.00 2386400000.00 -233400000.00 1666900000.00 29800000.00 183300000.00 1595900000.00 6753400000.00 1195900000.00 -7369000000.00 -6173100000.00 806200000.00 -537900000.00 268300000.00 0.00 -6441400000.00 0.00 0.00 0.00 0.00 -6441400000.00 -24900000.00 -6466300000.00 -6466300000.00 0.00 1694100000.00 10 -38.02 -38.02 0.00 0.00 -38.02 -38.02 1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 3rd February, 2020. n n2. Effective 1st April, 2019, the Company adopted Ind AS 116 “Leases” and applied the same to the lease contracts existing on 1st April, 2019 using the modified retrospective approach, recognizing right-of-use asset and adjusted lease liability. Accordingly, comparatives for the year ended 31st March, 2019 and other periods disclosed have not been retrospectively adjusted. The effect of the adoption is not significant to the result for the period(s). n n3. Following the recent decision to initiate a global voluntary recall (pharmacy/retail level) of ranitidine products including Zinetac in India, the Ultimate Holding Company is continuing with investigations into the potential source of the NDMA and has initiated a comprehensive strategic review of the impact of this recall on all related assets in India. As part of the ongoing strategic review, during the quarter, the Company has recognized financial impairment of Rs. 64031 Lacs connected to the under-utilisation of its manufacturing facilities and Rs. 9659 Lacs on account of other related assets / cost. nExceptional items for the quarter ended 31st December, 2018 of Rs. 2813 Lakhs comprise income from profit on sale of property Rs. 2344 Lakhs and sale of brands Rs. 469 Lakhs. n n4. The Company has elected to exercise the option permitted u/s 115BAA of the Income- tax Act, 1961 as introduced by the Taxation Laws (Amendment) Act, 2019. Accordingly, the Company has recognised Provision for Income tax for the nine months ended 31st December, 2019 and re-measured its net Deferred Tax Assets basis the rate prescribed in the said section. The full impact of this change has been recognised in the Statement of Profit and Loss for the nine months ended 31st December, 2019. Tax expense includes charge on account of exceptional items Rs. 1828 Lakhs, prior year charge of Rs. 2486 Lakhs and impact on net deferred tax due to change in tax rates Rs. 1692 Lakhs of which Rs.50 Lakhs is accounted in Other Comprehensive Income. n n5. In accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, the Statutory Auditors have carried out a limited review of the standalone financial results for the quarter and nine months ended 31st December, 2019. n n6. The Company has only one reportable segment which is Pharmaceuticals. Accordingly, no separate disclosures of segment information have been made. n n7. Previous periods' figures have been re-grouped / re-classified wherever necessary. Single segment 2019-04-01 2019-12-31 Unaudited Standalone 24488000000.00 624000000.00 25112000000.00 3760500000.00 6676400000.00 -152800000.00 4569700000.00 48300000.00 600900000.00 4790500000.00 20293500000.00 4818500000.00 -3357600000.00 1460900000.00 2022400000.00 -282600000.00 1739800000.00 0.00 -278900000.00 0.00 0.00 0.00 0.00 -278900000.00 -45100000.00 -324000000.00 -324000000.00 0.00 1694100000.00 10 -1.65 -1.65 0.00 0.00 -1.65 -1.65 Other Expenses 1595900000.00 Other Expenses 4790500000.00